|
1
|
Bursi F, McNallan SM, Redfield MM, Nkomo
VT, Lam CS, Weston SA, Jiang R and Roger VL: Pulmonary pressures
and death in heart failure: A community study. J Am Coll Cardiol.
59:222–231. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barst RJ, Ertel SI, Beghetti M and Ivy DD:
Pulmonary arterial hypertension: A comparison between children and
adults. Eur Respir J. 37:665–677. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guo H: Applied research of specific
phosphodiesterase inhibitor during perioperative period of
rheumatic valvular disease combining with pulmonary hypertension
(unpublished PhD thesis). Southern Medical University. 2012.
|
|
4
|
Yu Y and Shi J: Effect of milrinone on
pulmonary function and dynamics of congenital heart disease with
pulmonary hypertension in patients with pulmonary oxygen. J
Practical Med. 28:469–470. 2012.
|
|
5
|
Xu D: Effect of milrinone on pulmonary
hypertension after cardiac surgery. Guide Chin Med. 11:200–202.
2013.(In Chinese).
|
|
6
|
Yao B, Da G, Li Y, Wu J, Li Z, Yang Y, Zhu
J, Wang W and Yang J: The protective effect of milrinone on heart
function in plateau region in children with congenital heart
disease and pulmonary hypertension after operation. Shandong Med J.
54:49–51. 2014.(In Chinese).
|
|
7
|
Galiè N, Hoeper MM, Humbert M, Torbicki A,
Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS,
et al: Guidelines for the diagnosis and treatment of pulmonary
hypertension: The Task force for the diagnosis and treatment of
pulmonary hypertension of the European society of cardiology (ESC)
and the European Respiratory Society (ERS), endorsed by the
International society of heart and lung transplantation (ISHLT).
Eur Heart J. 30:2493–2537. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yock PG and Popp RL: Noninvasive
estimation of right ventricular systolic pressure by Doppler
ultrasound in patients with tricuspid regurgitation. Circulation.
70:657–662. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Trammell AW, Pugh ME, Newman JH, Hemnes AR
and Robbins IM: Use of pulmonary arterial hypertension-approved
therapy in the treatment of non-group 1 pulmonary hypertension at
US referral centers. Pulm Circ. 5:356–363. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li A, Xue C, Song M, MA S and Jia W: The
clinical efficacy and safety of oral administration of atorvastatin
in patients with pulmonary hypertension with left heart disease.
Ningxia Med J. 37:319–321. 2015.(In Chinese).
|
|
11
|
Lian X, Yang G and Wang E: Efficacy of
levosimendan combined with sildenafil in the treatment of chronic
heart failure with pulmonary hypertension. Practical J. 40:14–16.
2013.
|
|
12
|
Shipley JB, Tolman D, Hastillo A and Hess
ML: Milrilone: Basic and clinical pharmacology and acute and
chronic management. Am J Med Sci. 311:286–291. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schudt C, Winder S, Forderkunz S,
Hatzelmann A and Ullrich V: Influence of selective
phosphodiesterase inhibitors on human neutrophil functions and
levels of cAMP and Cai. Naunyn Schmiedebergs Arch Pharmacol.
344:682–690. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kume M, Banafsche R, Yamamoto Y, Yamaoka
Y, Nobiling R, Gebhard MM and Klar E: Dynamic changes of
post-ischemic hepatic microcirculation improved by a pre-treatment
of phosphodiesterase-3 inhibitor, milrinone. J Surg Res.
136:209–218. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Endres S, Sinba B and Fulle HJ: Amrinone
suppresses the synthesis of tumor necrosis factor-alpha in human
mononuclear cells. Shock. 1:377–380. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kawamura A, Yoshikawa T, Takahashi T,
Hayashi T, Takahashi E, Anzai T, Sato T and Ogawa S: Randomized
trial of phosphodiesterase inhibitors versus catecholamines in
patient with acutely decompensated heart failure. Jpn Circ J.
65:858–862. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lanfear DE, Hasan R, Gupta RC, Williams C,
Czerska B, Tita C, Bazari R and Sabbah HN: Short term effects of
milrinone on biomarkers of necrosis, apoptosis, and inflammation in
patients with severe heart failure. J Transl Med. 29:672009.
View Article : Google Scholar
|
|
18
|
Siflinger-Bimboim A, Bode DC and Malik AB:
Adenosine 3′,5′-cyclic monophosphate attenuates neutrophil-mediated
increase in endothelial permeability. Am J Physiol. 264:H370–H375.
1993.PubMed/NCBI
|
|
19
|
Fleming GA, Murray KT, Yu C, Byrne JG,
Greelish JP, Petracek MR, Hoff SJ, Ball SK, Brown NJ and Pretorius
M: Milrinone use is associated with post-operative atrial
fibrillation after cardiac surgery. Circulation. 118:1619–1625.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lamarche Y, Malo O, Thorin E, Denault A,
Carrier M, Roy J and Perrault LP: Inhaled but not intravenous
milrinone prevents pulmonary endothelial dysfunction after
cardiopumonary bypass. J Thorac Cardiovasc Surg. 130:83–92. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Burgess MI, Mogulkoc N, Bright-Thomas RJ,
Bishop P, Egan JJ and Ray SG: Comparison of echocardiographic
markers of right ventricular function in determining prognosis in
chronic pulmonary disease. J Am Soc Echocardiogr. 15:633–639. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Y, Wang Y, Zhai Z, Guo X, Yang Y and Lu
X: Real-time three-dimensional echocardiography to assess right
ventricle function in patients with pulmonary hypertension. PLoS
One. 10:e01295572015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Galiè N, Humbert M, Vachiery JL, Gibbs S,
Lang I, Torbicki A, Simonneau G, Peacock A, Noordegraaf Vonk A,
Beghetti M, et al: 2015 ESC/ERS Guidelines for the diagnosis and
treatment of pulmonary hypertension: The joint task force for the
diagnosis and treatment of pulmonary hypertension of the European
Society of Cardiology (ESC) and the European Respiratory Society
(ERS): Endorsed by: Association for European Paediatric and
Congenital Cardiology (AEPC), International Society for Heart and
Lung Transplantation (ISHLT). Eur Heart J. 37:67–119. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Harbaum L, Hennigs JK, Baumann HJ,
Lüneburg N, Griesch E, Bokemeyer C, Grünig E and Klose H:
N-terminal pro-brain natriuretic peptide is a useful prognostic
marker in patients with pre-capillary pulmonary hypertension and
renal insufficiency. PLoS One. 9:e942632014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Andreassen AK, Wergeland R, Simonsen S,
Geiran O, Guevara C and Ueland T: N-terminal pro-B-type natriuretic
peptide as an indicator of disease severity in a heterogeneous
group of patients with chronic precapillary pulmonary hypertension.
Am J Cardiol. 98:525–529. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kolditz M, Seyfarth HJ, Wilkens H, Ewert
R, Bollmann T, Dinter C, Hertel S, Klose H, Opitz C, Grünig E, et
al: MR-proADM predicts exercise capacity and survival superior to
other biomarkers in PH. Lung. 193:901–910. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wesley MC, McGowan FX, Castro RA,
Dissanayake S, Zurakowski D and Dinardo JA: The effect of milrinone
on platelet activation as determined by TEG platelet mapping.
Anesth Analg. 108:1425–1429. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kikura M, Lee MK, Safon RA, Bailey JM and
Levy JH: The effects of milrinone on platelets in patients
undergoing cardiac surgery. Anesth Analg. 81:44–48. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Baruch L, Patacsil P, Hameed A, Pina I and
Loh E: Pharmacodynamic effects of milrinone with and without a
bolus loading infusion. Am Heart J. 141:266–273. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang LY and Yang Y: Clinical study of
milrinone in the treatment of neonatal persistent pulmonary
hypertension. Straits Sci. 8:111–113. 2012.(In Chinese).
|
